fumiquinazoline C: structure in first source
fumiquinazoline C : A fumiquinazoline obtained by oxidative spirocyclisation of fumiquinazoline A.
ID Source | ID |
---|---|
PubMed CID | 11339719 |
CHEBI ID | 64551 |
SCHEMBL ID | 12931224 |
MeSH ID | M0424394 |
Synonym |
---|
fumiquinazoline c |
(1s,2's,3s,5r,9a's)-1,2'-dimethyl-1',9a'-dihydro-4h-spiro[1,5-(epiminomethano)[1,4]oxazepino[3,4-b]quinazoline-3,9'-imidazo[1,2-a]indole]-3',7,13(1h,2'h,5h)-trione |
CHEBI:64551 |
SCHEMBL12931224 |
(1r,2's,3'as,12s,14s)-2',12-dimethylspiro[13-oxa-2,10,17-triazatetracyclo[10.3.2.02,11.04,9]heptadeca-4,6,8,10-tetraene-14,4'-3,3a-dihydro-2h-imidazo[1,2-a]indole]-1',3,16-trione |
DTXSID80893275 |
140924-01-2 |
Q27133343 |
C22148 |
Class | Description |
---|---|
fumiquinazoline | A group of indole alkaloids biosynthesised using L-tryptophan, L-alanine and anthranilic acid building blocks. |
imidazoindole | Any organic heterotricyclic compound that consists of an imidazole ring ortho-fused to an indole. |
oxaspiro compound | A spiro compound in which at least one of the cyclic components is an oxygen heterocyle. |
azaspiro compound | An azaspiro compound is a spiro compound in which at least one of the cyclic components is a nitrogen heterocyle. |
organic heteroheptacyclic compound | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Pathway | Proteins | Compounds |
---|---|---|
fumiquinazoline D biosynthesis | 5 | 15 |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (33.33) | 29.6817 |
2010's | 3 (50.00) | 24.3611 |
2020's | 1 (16.67) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |